Analysis Of Clinical Features And Relapse Factors Of Borderline Ovarian Tumors

Borderline ovarian tumor (BOT) is a tumor with low potential malignancy, and more often occurred in women of reproductive age, for some patients who has needs of fertility, the conservative surgeries were usually performed. So, how is the recurrence of conservative surgery (which can retain reproductive function or endocrine function)? How is its risk? At present, there were fewer literatures researching on these aspects.Objective: To explore the related factors of recurrence based on the analysis on clinical characteristics and recurrence causes of borderline ovarian tumors.Methods:279cases of patients with intraoperatively or postoperatively pathological diagnosis of BOT from Jan,1997to Dec,2012were selected, and their diagnoses were confirmed according to the BOT pathology diagnostic criteria of WHO. Based on the personal medical record of these patients, coupled with the correspondence and telephone following‐up on the absence or presence of postoperative recurrence, treatment methods for recurrence, these data were indexed into a database and analyzed by SPSS17.0software.Results:279cases of BOT patients had onset ages at15‐82years old, their average ages were39.66±15.62years, in which, MBOT accounted for44.09%, SBOT accounted53.76%, mixed BOT accounted for14.34%, endometrioid BOT accounted for0.72%.239cases of stage Ⅰ patients (85.66%),6cases of stage Ⅱ patients (2.15%),34cases of stage Ⅲpatients (12.19%), no stage Ⅳ patients. CA125positive rate in stage Ⅰ BOT patients was27.62%, that in stage Ⅱ or above stage BOT patients was84.62%, the detection of CA125for the diagnosis of stage Ⅱ or above stage BOT patients was more than significant for stage Ⅰ BOT patients (P <0.05).171cases of patients were taken conservative surgeries and23cases of them relapsed;108cases of patients were taken radical surgeries and9cases of them relapsed; and among the56cases of patients took chemotherapy,10cases (34.48%) relapsed after surgeries.Conclusion: BOT conservative surgery has a risk of recurrence. The BOT patients should receive aggressive surgical treatment, in which, except patients who have fertility requirements, the remaining patients should receive comprehensive staging surgeries. Whether the adjuvant chemotherapy is needed for BOT patients or not, it should also be individualized, for example, the early non‐invasive plant BOT patients may not need chemotherapy. The patients with relapsed BOT should be taken surgery actively. The main factors affecting the BOT prognosis includes: the FIGO stage of surgery, whether the pathological findings existed micro‐invasive, whether the ovary at the ill side was retained.